Novavax Inc vs Johnson & Johnson
NVAX vs JNJ — side-by-side comparison from reported financials. NVAX leads 4, JNJ leads 5 of 9 comparable metrics.
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | NVAX | JNJ |
|---|---|---|
| Price | $12.73 | $261.79 |
| Market cap | $2.10B | $631B |
| Revenue (TTM) | $414M | $97.9B |
| Revenue growth | -17.2% | +5.6% |
| Net margin | -59.9% | 21.5% |
| Free cash flow | -$42.8M | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | +48.2% | +37.0% |
| P/E | 4.8 | 29.9 |
| P/E vs own history (cheap-side %) | 29% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 283% | 26% |
| Altman Z-score | -5.14 | — |
| CV checks passed | 4 of 10 | 10 of 10 |
| Employees | 749 | 140,800 |
Full résumé-style profiles: NVAX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.